ReviewNPJ vaccines2020
Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines.
Review in NPJ vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Preformulated, Shelf-Stable, Dendritic Cell-Targeting Nanogel mRNA Vaccine Delivery Platform.Bioconjugate chemistry · 2026Article
- Development of a single-dose Q fever vaccine with an injectable nanoparticle-loaded hydrogel: effect of sustained co-delivery of antigen and adjuvant.Drug delivery · 2025Article
- Rational Development of a Novel Emulgel Adjuvant for Single-Shot Effective Vaccination: A Multivariate Analysis Approach.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Dose-sparing effects of novel adjuvants and aluminum hydroxide on two different vaccines in a neonatal mouse model.Frontiers in immunology · 2025Article
- Impact of lactobacillus probiotics on vaccine response in diabetic rats: modulation of inflammatory cytokines.American journal of clinical and experimental immunology · 2025Article
- M2e-Derived Peptidyl and Peptide Amphiphile Micelles as Novel Influenza Vaccines.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Adjuvanted Modified Bacterial Antigens for Single-Dose Vaccines.International journal of molecular sciences · 2024Article
- Article
- Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice.iScience · 2022Article
- Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.Pharmaceutics · 2022Review
- A novel built-in adjuvant metallothionein-3 aids protein antigens to induce rapid, robust, and durable immune responses.Frontiers in immunology · 2022Article
- Strategies to Overcome the Barrier of Ischemic Microenvironment in Cell Therapy of Cardiovascular Disease.International journal of molecular sciences · 2021Review
- Looking beyond COVID-19 vaccine phase 3 trials.Nature medicine · 2021Review
- A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections.Frontiers in pharmacology · 2021Review
- Recent Development of Ruminant Vaccine Against Viral Diseases.Frontiers in veterinary science · 2021Review
- Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19.Case reports in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines represent the most successful medical intervention in history, with billions of lives saved. Although multiple doses of the same vaccine are typically required to reach an adequate level of protection, it would be advantageous to develop vaccines that induce protective immunity with fewer doses, ideally just one. Single-dose vaccines would be ideal to maximize vaccination coverage, help stakeholders to greatly reduce the costs associated with vaccination, and improve patient convenience. Here we describe past attempts to develop potent single dose vaccines and explore the reasons they failed. Then, we review key immunological mechanisms of the vaccine-specific immune responses, and how innovative technologies and approaches are guiding the preclinical and clinical development of potent single-dose vaccines. By modulating the spatio-temporal delivery of the vaccine components, by providing the appropriate stimuli to the innate immunity, and by designing better antigens, the new technologies and approaches leverage our current knowledge of the immune system and may synergize to enable the rational design of next-generation vaccination strategies. This review provides a rational perspective on the possible development of future single-dose vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.